The Rechallenge of ADCs in MBC Patients

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.

NCT04395989 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor

NCT03842085 ·Status: RECRUITING ·Phase: PHASE1

Reverse HER2-negative Immune Resistant Breast Cancer

NCT06731140 ·Status: RECRUITING ·Phase: PHASE2

Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)

NCT05909332 ·Status: RECRUITING ·Phase: PHASE3

Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer

NCT06877416 ·Status: RECRUITING

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

NCT03500380 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3

B002 in Patients With HER2-positive Breast Cancer

NCT04382352 ·Status: COMPLETED ·Phase: PHASE1

Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer

NCT07005557 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment

NCT06914661 ·Status: ENROLLING_BY_INVITATION

Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer

NCT07162259 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

NCT05088057 ·Status: UNKNOWN ·Phase: PHASE2

A Study of A166 in Patients With Advanced Solid Malignant Tumors

NCT05311397 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

NCT05954442 ·Status: RECRUITING ·Phase: PHASE3

Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

NCT06470672 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

NCT05532696 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

NCT05331326 ·Status: UNKNOWN ·Phase: PHASE2

Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC

NCT04001634 ·Status: COMPLETED

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

NCT06121557 ·Status: RECRUITING ·Phase: PHASE1

SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases

NCT06210438 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

NCT06057610 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

NCT06188559 ·Status: COMPLETED ·Phase: PHASE2

A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer

NCT05629949 ·Status: COMPLETED ·Phase: PHASE3

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

NCT04355858 ·Status: UNKNOWN ·Phase: PHASE2

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

NCT05205200 ·Status: RECRUITING ·Phase: PHASE2

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

NCT05981001 ·Status: RECRUITING ·Phase: PHASE1/PHASE2